See more : Cloudcall Group plc (CALL.L) Income Statement Analysis – Financial Results
Complete financial analysis of Molecular Partners AG (MOLN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Molecular Partners AG, a leading company in the Biotechnology industry within the Healthcare sector.
- CG-VAK Software and Exports Limited (CGVAK.BO) Income Statement Analysis – Financial Results
- ELMO Software Limited (ELO.AX) Income Statement Analysis – Financial Results
- ELMO Software Limited (ELMFF) Income Statement Analysis – Financial Results
- PT Formosa Ingredient Factory Tbk (BOBA.JK) Income Statement Analysis – Financial Results
- 2020 Bulkers Ltd. (0FF.F) Income Statement Analysis – Financial Results
Molecular Partners AG (MOLN)
About Molecular Partners AG
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.04M | 189.56M | 9.33M | 9.34M | 20.38M | 10.36M | 20.02M | 23.04M | 29.12M | 26.63M | 32.42M |
| Cost of Revenue | 47.84M | 50.75M | 55.72M | 56.08M | 43.50M | 15.60M | 17.82M | 14.57M | 1.17M | 170.75K | 1.22M |
| Gross Profit | -40.81M | 138.81M | -46.39M | -46.73M | -23.12M | -5.25M | 2.19M | 8.47M | 27.95M | 26.45M | 31.20M |
| Gross Profit Ratio | -579.80% | 73.23% | -497.19% | -500.12% | -113.40% | -50.67% | 10.96% | 36.76% | 96.00% | 99.36% | 96.23% |
| Research & Development | 48.78M | 50.75M | 55.72M | 56.08M | 43.50M | 38.20M | 37.45M | 35.19M | 23.92M | 18.79M | 20.82M |
| General & Administrative | 19.00M | 21.82M | 16.91M | 11.03M | 13.16M | 9.46M | 8.28M | 7.24M | 6.22M | 4.90M | 3.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 57.00K | 5.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 84.54K |
| SG&A | 19.00M | 21.82M | 16.91M | 11.03M | 13.16M | 9.46M | 8.28M | 7.24M | 6.22M | 4.90M | 3.59M |
| Other Expenses | -47.48M | 372.00K | 125.00K | 568.00K | 381.00K | -9.76M | -12.12M | -9.38M | 4.16M | 4.29M | 2.29M |
| Operating Expenses | 20.30M | 72.94M | 72.75M | 67.67M | 57.04M | 47.77M | 45.86M | 42.53M | 31.34M | 24.78M | 25.30M |
| Cost & Expenses | 68.15M | 72.94M | 72.75M | 67.67M | 57.04M | 47.77M | 45.86M | 42.53M | 31.34M | 24.78M | 25.30M |
| Interest Income | 4.28M | 1.14M | 99.00K | 367.00K | 1.60M | 693.00K | 610.00K | 335.00K | 357.52K | 347.85K | 234.82K |
| Interest Expense | 49.00K | 605.00K | 548.00K | 271.00K | 27.00K | 591.00K | 197.00K | 89.00K | 216.00 | 853.00 | 226.53K |
| Depreciation & Amortization | 2.42M | 2.39M | 2.57M | 2.89M | 2.47M | 924.00K | 1.15M | 1.09M | 909.39K | 809.53K | 793.02K |
| EBITDA | -59.53M | 120.85M | -60.85M | -59.59M | -33.71M | -36.27M | -24.70M | -18.06M | -1.02M | -1.47M | 7.93M |
| EBITDA Ratio | -845.84% | 63.37% | -651.25% | -589.73% | -160.26% | -350.25% | -120.35% | -78.39% | -3.51% | 11.23% | 25.10% |
| Operating Income | -61.11M | 116.61M | -63.42M | -58.33M | -36.66M | -37.41M | -25.84M | -19.49M | -2.22M | 1.84M | 7.12M |
| Operating Income Ratio | -868.26% | 61.52% | -679.72% | -624.21% | -179.86% | -361.27% | -129.12% | -84.57% | -7.62% | 6.91% | 21.95% |
| Total Other Income/Expenses | -876.00K | 1.24M | -365.00K | -4.45M | 389.00K | 374.00K | 414.00K | 874.00K | 2.07M | -4.12M | 24.93K |
| Income Before Tax | -61.98M | 117.85M | -63.78M | -62.78M | -36.27M | -37.04M | -25.43M | -18.61M | -148.82K | -2.28M | 7.14M |
| Income Before Tax Ratio | -880.70% | 62.17% | -683.63% | -671.82% | -177.95% | -357.66% | -127.05% | -80.78% | -0.51% | -8.57% | 22.03% |
| Income Tax Expense | 0.00 | -1.24M | 2.00K | -11.00K | 17.00K | -591.00K | -414.00K | -874.00K | -2.07M | 4.12M | -226.53K |
| Net Income | -61.98M | 117.85M | -63.79M | -62.76M | -36.29M | -37.04M | -25.43M | -18.61M | -148.82K | -2.28M | 7.14M |
| Net Income Ratio | -880.70% | 62.17% | -683.65% | -671.70% | -178.03% | -357.66% | -127.05% | -80.78% | -0.51% | -8.57% | 22.03% |
| EPS | -1.89 | 3.63 | -2.06 | -2.51 | -1.69 | -1.75 | -1.22 | -0.91 | -0.01 | -0.15 | 0.37 |
| EPS Diluted | -1.89 | 3.54 | -2.06 | -2.51 | -1.69 | -1.75 | -1.22 | -0.91 | -0.01 | -0.15 | 0.37 |
| Weighted Avg Shares Out | 32.77M | 32.47M | 31.01M | 25.00M | 21.41M | 21.17M | 20.86M | 20.43M | 19.54M | 15.22M | 19.49M |
| Weighted Avg Shares Out (Dil) | 32.77M | 33.27M | 31.01M | 25.00M | 21.41M | 21.17M | 20.86M | 20.43M | 19.54M | 15.29M | 19.49M |
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero
Molecular Partners to Present Additional Preclinical Data Supporting the Company's Radio DARPin Therapy Platform at AACR
Molecular Partners AG (MOLN) Q4 2022 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports